Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Daily News

PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures

L.A. McKeown

January 18, 2023

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

Obesity May Boost Thrombotic Events in Contraceptive Users, Review Suggests

L.A. McKeown

September 16, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

L.A. McKeown

December 21, 2021

News Daily News

Thrombotic Events Frequent Among COVID-19 Patients in ICUs

Michael O'Riordan

October 27, 2020

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

Caitlin E. Cox

September 04, 2020

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

Yael L. Maxwell

May 12, 2020

News Daily News

Testosterone Therapy Ups VTE Risk, Even When Indicated

Caitlin E. Cox

November 12, 2019

News Daily News

Hormone Therapy Ups CV Risk in Transgender Individuals

Caitlin E. Cox

February 18, 2019

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

L.A. McKeown

December 06, 2018

News Daily News

More Research Supports Use of Aspirin Alone to Prevent VTE After Knee Replacement Surgery

L.A. McKeown

October 18, 2018

News Daily News

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Caitlin E. Cox

December 12, 2017

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

L.A. McKeown

March 18, 2017

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

Advertisement

November 2024 Dispatch for the CV Team

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

Obesity May Boost Thrombotic Events in Contraceptive Users, Review Suggests

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

FDA Approves Two Additional Indications for Rivaroxaban in Children

Thrombotic Events Frequent Among COVID-19 Patients in ICUs

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

New AHA Guidance on Hospital VTE Stresses Risk Assessment, Standardization

Testosterone Therapy Ups VTE Risk, Even When Indicated

Hormone Therapy Ups CV Risk in Transgender Individuals

NOACs Significantly Curb Risk of VTE in Cancer Patients

More Research Supports Use of Aspirin Alone to Prevent VTE After Knee Replacement Surgery

USPSTF Upholds Stance Against Hormone Therapy to Prevent Chronic Diseases in Menopausal Women

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

肺栓塞发作后，二级抗凝效果未持续

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content